Question-and-Answer Session
Thank you. Today's question and answer session will be conducted electronically. [Operator Instructions]. And our first question comes from the line of Thomas Wei with Piper Jaffray. Go ahead.
Thomas Wei - Piper Jaffray & Co.
Hi, thanks very much. I wanted to ask about the market share trends in the HIV franchise. It's very tough to see that there has been any movement in the back of your share in the U.S. so far. When do you think is the right time to see those market start shifting? What is the catalyst that's going to get that going?
Kevin Young - Executive Vice President, Commercial Operations
Hi Thomas, it's Kevin. I'll talk about... focus on the U.S., although I think it's also important that we also talk about Europe because I think we've seen a different pattern over in Europe, especially in the UK. But focusing on the U.S., I think it is a little early to see an impact. Honestly, we haven't the full publication, or we won't do until World AIDS of 5202. And it seems that in the U.S. 5202 has more interest than DAD, DAD being a European cohort study. So I think there is more interest in the ACTG 5202. So I think we're going to see a reaction to that post Mexico. And I think that's going to start to sort of raise the discussion and debate again about the use of abacavir. So I think it's going to take that as a pivotal point in this debate.
Operator
Our next question comes from the line of Meg Malloy with Goldman Sachs. Go ahead.
Margaret Malloy - Goldman Sachs & Co.
Thanks very much. I am wondering if you have any better handle on what the actual purchasing levels were for the ADAP programs in Q1.
John F. Milligan, PhD - President and Chief Operating Officer
Meg, it's John. We don't know the actual number. I can tell you that the two largest systems that we saw purchasing in the ADAP system were Florida and Taxes. Florida started to order really only very late in the quarter and Texas only at the very, very end of the quarter. So we were almost completed devoid of sales into two systems during the course of the quarter. We don't know what the demand is there and we certainly don't know how much was on hand. It was, I would say, a little bit more than we had even forecasted. So it was significant.
- To read the full transcript on Seeking Alpha, click here »
